Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Apexigen  (Stock symbol: APGN )

863 Mitten Road #103
Burlingame, CA 94010
USA
650-931-6236
Website Company Summary Management Team
Management

CEO: Xiaodong Yang (8/13/2010); Xiaodong Yang (7/31/2010)
President/COO/Operations: Francis Sarena (01/31/2022)
General Management: Frank Hsu (09/30/2021)
Finance: Amy Wong (2/28/2014) ; Linda Rubinstein (11/30/2018) ; William Duke (6/8/2022)
Business Development: Mark Nevins
Former Employees: Ovid Trifan Yongke Zhang
Board

Outside board: (May no longer be on the board) George J Lee (AmKey Ventures General Partner);  Herb C Cross (Atreca CFO)
Company

Business description: Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.
Partners include: Bristol-Myers Squibb ;  Centocor ResearchAndDevelopment
Capital

Rounds: 4
Recent Fundings: Mar 2020   Jul 2018
Capital raised: 216.0M
Last Round: 123.1M
Ownership: Private   Ipo Filing
Stock Symbol: APGN
VCs include: Sycamore Ventures China Development Industrial Bank Kenson Ventures;  AmKey Ventures ;  Decheng Capital ;  WSR Capital ;  Themes Investment Partners SV Tech Ventures ;  3E Bioventures Capital ;  Virtus Inspire Ventures ;  Oceanpine Capital

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2022
Sector: Biotech
Year Founded: 2010
Headcount: 26-50 as of Mar 2022
Rounds: 4
Recent Fundings: Mar 2020   Jul 2018
Capital Raised: 216.0M
Last Round: 123.1M
Ownership: Private   Ipo Filing
Stock Symbol: APGN